Sunil Srivastava, MD, reviews the key efficacy outcomes in the MUST trial and provides potential explanations for the differences in efficacy outcomes in the first 2-4 years of the study versus later timepoints.
RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Click here for full prescribing information on RETISERT®
RETISERT and RETISERT READY are trademarks of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates.